MedTrace Logo

Drug-Drug Interaction Study of Chiglitazar in Healthy Subjects.

NCT05681273 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 48

Last updated 2023-06-15

No results posted yet for this study

Summary

This Phase 1 open label study is being conducted to characterize the pharmacokinetic (PK) and safety profiles of Chiglitazar with Empagliflozin，Atorvastatin and Valsartan in healthy subjects.

Conditions

  • T2DM

Interventions

DRUG

Chiglitazar

Chiglitazar 48mg

DRUG

Empagliflozin

Empagliflozin 10mg

DRUG

Atorvastatin

Atorvastatin 20mg

DRUG

Valsartan

Valsartan 160mg

Sponsors & Collaborators

  • Chipscreen Biosciences, Ltd.

    lead INDUSTRY

Principal Investigators

  • Hongrong Xu · Shanghai Zhongshan Hospital

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-02-17
Primary Completion
2023-03-21
Completion
2023-03-21

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05681273 on ClinicalTrials.gov